临床医生能从治疗性研究中了解急性口服甲氨蝶呤中毒的哪些处理要点
该文综述了甲氨蝶呤(MTX)的药代动力学及高剂量治疗研究,并回顾性审计了新南威尔士毒物信息中心2004年4月至2015年7月共51例急性口服MTX中毒病例(15例儿童意外摄入、36例故意中毒)。儿童意外摄入中位剂量50 mg、中位年龄2岁;故意中毒中位年龄47岁、中位剂量325 mg;19例测血药浓度者均显著低于肿瘤治疗浓度及亚叶酸钙解救列线图线,无不良后遗症。作者结论:因吸收饱和,急性口服过量不会达到接近1 g/m²静脉MTX的生物利用度,急性摄入无需治疗、无需监测浓度,除非肾功能衰竭或延迟摄入。
要点
- 儿童意外摄入中位剂量50 mg(IQR 10–100,范围10–150),中位年龄2岁(IQR 2–2,范围1–4),177例急性口服中毒未报告严重毒性。
- 36例故意中毒中位年龄47岁(IQR 31–62,范围10–85)、中位剂量325 mg(IQR 85–500,范围40–1000)。
- 19例测血药浓度者均显著低于肿瘤治疗浓度及亚叶酸钙解救列线图线,无不良后遗症。
- 单次急性口服摄入无需治疗;大量摄入>1 g/m²可口服亚叶酸钙进一步降低生物利用度。
- 延迟摄入>36 h或急性过量伴肾功能不全(eGFR<45 mL/min/1.73 m²)可先口服后静脉给亚叶酸钙。
适用人群与场景
- 急性口服甲氨蝶呤中毒患者,包括儿童意外摄入和成人故意中毒。
- 不适用于延迟摄入>36 h或伴肾功能不全(eGFR<45 mL/min/1.73 m²)者,这类患者需亚叶酸钙治疗。
诊断标准与关键阈值
- 急性口服中毒无需常规监测MTX血药浓度。
- 肾功能不全阈值:eGFR<45 mL/min/1.73 m²。
- 延迟摄入定义:>36 h。
处置流程与药物剂量
- 单次急性口服摄入:因MTX生物利用度低,无需治疗。
- 大量摄入>1 g/m²:可口服亚叶酸钙以进一步降低生物利用度。
- 延迟摄入>36 h或急性过量伴肾功能不全(eGFR<45 mL/min/1.73 m²):可先口服后静脉给予亚叶酸钙。
- 急性口服中毒无需监测MTX血药浓度。
红旗征与不能漏的情况
- 延迟摄入>36 h。
- 急性过量伴肾功能不全(eGFR<45 mL/min/1.73 m²)。
研究设计与关键结果
- 系统检索Embase(1974年至2016年10月)和Medline(1946年至2016年10月),分别检出25、135、109和365篇文献;15篇提供急性摄入临床数据,18篇为高剂量MTX(>1 g/m²体表面积)单药化疗的药代动力学或临床数据,30篇用于综述毒性剂量、药代动力学、危险因素、临床症状和管理。
- 回顾性审计新南威尔士毒物信息中心2004年4月至2015年7月记录:51例急性MTX中毒,其中15例儿童意外摄入(中位剂量50 mg,IQR 10–100,范围10–150;中位年龄2岁,IQR 2–2,范围1–4),36例故意中毒(中位年龄47岁,IQR 31–62,范围10–85;中位剂量325 mg,IQR 85–500,范围40–1000)。
- 19例测血药浓度者均显著低于肿瘤治疗浓度及亚叶酸钙解救列线图线,无患者报告不良后遗症。
- 177例急性口服MTX中毒未报告严重毒性。
证据类型、等级与局限
- 证据类型:系统综述结合回顾性审计。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为:因吸收饱和导致MTX生物利用度低,儿童意外摄入或成人故意急性口服过量均不会引起毒性。
- 作者认为:急性口服过量不会达到接近1 g/m²静脉MTX的生物利用度,因此急性摄入无需治疗,除非患者有肾功能衰竭或延迟摄入。
- 作者认为:急性口服MTX中毒无需监测血药浓度。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
CONTEXT: Methotrexate (MTX) is an anti-folate drug that has been utilized in both malignant and chronic inflammatory conditions. Doctors are often concerned with a potential adverse outcome when managing patients with acute oral MTX poisoning given its potential for serious adverse reactions at therapeutic doses. However, there is surprisingly little data from acute poisoning cases and more data from the therapeutic use of high-dose MTX.
OBJECTIVES: To review pharmacokinetic and pharmacological properties of MTX and systematically review series of acute MTX poisonings and therapeutic studies on high-dose MTX that provide pharmacokinetic or clinical data.
METHODS: An Embase (1974-October 2016) and Medline (1946-October 2016) search was performed by combining "MTX" and "overdose/poison" or "MTX" and "toxicity" or "MTX" and "high-dose MTX" or "MTX" and "bioavailability" or "pharmacokinetics"; 25, 135, 109 and 365 articles were found, respectively, after duplicates were removed. There were 15 papers that provided clinical data on acute ingestion and toxicity that occurred with low-dose administration. Eighteen papers were on high-dose MTX (>1 g per m2 body surface area) used as a single chemotherapy agent which provided pharmacokinetic or clinical data on MTX toxicity. Thirty papers were reviewed to determine the toxic dose, pharmacokinetics, risk factors, clinical symptoms and management of acute MTX toxicity. Given the limited acute poisoning data, a retrospective audit was performed through the consultant records of the New South Wales Poisons Information Centre from April 2004 to July 2015 to examine the clinical syndrome and toxicity of acute oral MTX poisoning. Pharmacokinetics: Reduced MTX bioavailability is a result of saturable absorption. Although maximal bioavailable absorption occurs at a dose of ∼15 mg m-2, splitting the dose increases bioavailability. MTX clearance is proportional to renal function. Acute toxicity: Oncologists prescribe doses up to 12 g m-2 of MTX. Patients treated with an intravenous dose of MTX <1g m-2 do not require folinic acid rescue. MTX toxicity correlates better with duration and extent of exposure than peak serum concentration. Acute oral poisoning: Acute oral MTX poisoning in 177 patients did not report any severe toxicity. In the New South Wales Poisons Information Centre audit data (2004-2015), 51 cases of acute MTX poisoning were reported, of which 15 were accidental paediatric ingestions. The median reported paediatric ingestion was 50 mg (IQR: 10-100; range: 10-150) with a median age of 2 years (IQR: 2-2; range: 1-4). Of the 36 patients with acute deliberate MTX poisoning, median age and dose were 47 years (IQR: 31-62; range: 10-85) and 325 mg (IQR: 85-500; range: 40-1000), respectively. Of the 19 patients who had serum MTX concentrations measured, all were significantly below the concentrations used in oncology and the folinic acid rescue nomogram line and no patient reported adverse sequelae. Management of acute oral poisoning: Due to the low bioavailability of MTX, treatment is not necessary for single ingestions. Oral folinic acid may be used to lower the bioavailability further with large ingestions >1 g m-2. Oral followed by intravenous folinic acid may be used in patients with staggered ingestion >36 h or patients with acute overdose and renal impairment (eGFR <45 mL/min/1.73 m2).
CONCLUSIONS: As a consequence of saturable absorption MTXs bioavailability is so low that neither accidental paediatric MTX ingestion nor acute deliberate MTX overdose causes toxicity. An acute oral overdose will not provide a bioavailable dose even close to 1 g m-2 of parenteral MTX. Hence, no treatment is required in acute ingestion unless the patient has renal failure or staggered ingestion. There is also no need to monitor MTX concentrations in acute oral MTX poisoning.
参考来源
- Chan BS, Dawson AH, Buckley NA, et al. What can clinicians learn from therapeutic studies about the treatment of acute oral methotrexate poisoning? Clin Toxicol (Phila). 2017. PMID: 28084171. doi:10.1080/15563650.2016.1271126
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。